We propose that a deeper understanding of the role played by different components of the tumor microenvironment, especially focused on the niche where micrometastasis sit, may lead to the development of new therapies that could eliminate these residual cells early during treatment and thus reduce the late recurrences that characterize ER+ breast cancer. Here, ESR1 is linked to breast cancer.